openPR Logo
Press release

Cognitive Impairment Associated With Schizophrenia (CIAS) Market was valued at USD 3.85 billion in 2024 and is projected to reach USD 6.90 billion by 2034

12-09-2025 12:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Exactitude Consultancy

Cognitive Impairment Associated With Schizophrenia (CIAS) Market

Cognitive Impairment Associated With Schizophrenia (CIAS) Market

Market Overview
The Cognitive Impairment Associated With Schizophrenia (CIAS) Market was valued at USD 3.85 billion in 2024 and is projected to reach USD 6.90 billion by 2034, growing at a CAGR of 6.2% during the forecast period.
Cognitive dysfunction-including deficits in attention, memory, executive function, social cognition, and processing speed-is one of the core features of schizophrenia and significantly affects long-term functionality, employment, and quality of life.

Growing awareness of CIAS as a distinct therapeutic need, expanding research pipelines targeting glutamatergic and cholinergic pathways, rising demand for cognitive-enhancing drugs, and increasing adoption of digital cognitive training tools are driving market growth.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71900

Market Dynamics
Drivers
• Rising global prevalence of schizophrenia affecting over 24 million people.
• Growing recognition that cognitive deficits persist despite antipsychotic treatment, creating strong unmet clinical need.
• Expansion of clinical trials targeting novel mechanisms such as NMDA receptor modulation, α7 nicotinic agonists, and TAAR1 agonists.
• Increasing adoption of digital neurocognitive training programs.
• Government and private investments in mental health research and early psychosis intervention programs.

Restraints
• Limited FDA-approved therapies specifically for CIAS.
• High dropout rates in schizophrenia clinical trials due to disease complexity.
• Social stigma and limited access to specialized psychiatric care in developing regions.
• Variability in cognitive assessment tools across clinical settings.

Opportunities
• Development of next-generation cognition-enhancing drugs.
• Integration of AI-driven cognitive assessment tools for continuous monitoring.
• Use of digital therapeutics to complement pharmacological treatment.
• Growing interest in early intervention programs targeting prodromal schizophrenia.
• Expansion of personalized psychiatry based on biomarkers and neuroimaging.

Market Growth Outlook (2024-2034)
The CIAS market will grow from USD 3.85 billion in 2024 to USD 6.90 billion in 2034, driven by innovations in neuropsychiatric therapeutics, increased investment in schizophrenia research, and rising adoption of digital cognitive technologies. Emerging therapies targeting neurotransmitter modulation are expected to revolutionize treatment.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71900/cognitive-impairment-associated-with-schizophrenia-market

Segmentation Analysis
By Treatment Type
Pharmacotherapy:
• Current antipsychotics have limited effect on cognition, prompting demand for novel adjunctive treatments.
• Promising drug candidates include NMDA receptor modulators, muscarinic receptor agonists, α7 nicotinic receptor agonists, PDE inhibitors, and TAAR1 agonists.
• Off-label use of stimulants and nootropics is seen in some clinical settings, though evidence is limited.

Cognitive Remediation Therapy (CRT):
• Considered the most evidence-based behavioral approach to improving memory, attention, and problem-solving.
• Increasing integration of CRT with psychosocial rehabilitation programs.

Digital & Neurotechnology Solutions:
• Mobile cognitive training apps, VR-based cognitive rehabilitation, and AI-driven personalized training are gaining traction.
• Digital therapeutics are expected to grow significantly over the next decade.

By End User
• Hospitals & Psychiatric Centers manage severe schizophrenia cases requiring comprehensive treatment.
• Mental Health Clinics deliver long-term cognitive remediation and pharmacological care.
• Research Institutions support advanced drug development and neurocognitive assessments.
• Digital Therapy Platforms increasingly deliver remote cognitive training.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71900

Regional Insights
North America
North America dominates the CIAS market due to strong investment in schizophrenia research, high awareness, adoption of digital cognitive tools, and active clinical trial pipelines. The U.S. leads in new drug development for CIAS.

Europe
Europe shows strong growth supported by established mental health policies, advanced cognitive rehabilitation programs, and increasing research collaborations across academic centers.

Asia Pacific
Asia Pacific is the fastest-growing region, driven by large unmet patient populations, rising mental health awareness, and expanding access to psychiatric care in China, Japan, South Korea, and India.

Latin America & Middle East/Africa
These regions show gradual improvement in schizophrenia management and increasing adoption of digital cognitive tools, but limited specialist access and stigma remain key challenges.

Competitive Landscape
The CIAS market includes pharmaceutical innovators, neuroscience research companies, and digital mental health platforms.

Key Companies Include:
• AbbVie
• Boehringer Ingelheim
• Roche
• Eli Lilly
• Pfizer
• Karuna Therapeutics
• Acadia Pharmaceuticals
• Takeda Pharmaceutical
• Alkermes
• MindMaze

• Pear Therapeutics (digital therapeutics)
These companies are investing in NMDA modulators, muscarinic agonists, TAAR1-based therapies, and digital cognitive remediation tools.

Recent Developments
• Strong pipeline of NMDA receptor modulators showing cognitive enhancement potential.
• Growing interest in muscarinic M1/M4 agonists as candidates for improving cognition.
• Expansion of VR-based cognitive remediation programs in psychiatry.
• FDA breakthrough therapy designations for select schizophrenia-related cognitive drug candidates.
• Increasing integration of AI-based cognitive assessment tools in clinical settings.

This report is also available in the following languages : Japanese (統合失調症に伴う認知障害市場), Korean (정신분열증과 관련된 인지 장애 시장), Chinese (与精神分裂症相关的认知障碍市场), French (Marché des troubles cognitifs associés à la schizophrénie), German (Markt für kognitive Beeinträchtigungen im Zusammenhang mit Schizophrenie), and Italian (Deficit cognitivo associato al mercato della schizofrenia), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71900

Our More Reports:

Cushing's Syndrome Market
https://exactitudeconsultancy.com/reports/72650/cushing-s-syndrome-market

Diabetic Foot Market
https://exactitudeconsultancy.com/reports/72010/diabetic-foot-market

Donohue syndrome Market
https://exactitudeconsultancy.com/reports/72012/donohue-syndrome-market

Endometriosis Pain Market
https://exactitudeconsultancy.com/reports/72014/endometriosis-pain-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cognitive Impairment Associated With Schizophrenia (CIAS) Market was valued at USD 3.85 billion in 2024 and is projected to reach USD 6.90 billion by 2034 here

News-ID: 4307653 • Views:

More Releases from Exactitude Consultancy

Huntington's Disease Market is expected to reach USD 1.21 billion by 2034
Huntington's Disease Market is expected to reach USD 1.21 billion by 2034
The global Huntington's Disease (HD) Market was valued at USD 602 million in 2024 and is expected to reach USD 1.21 billion by 2034, growing at a CAGR of 7% during the forecast period (2025-2034). The market is driven by increased diagnosis through genetic testing, rising awareness of hereditary neurodegenerative disorders, improved symptomatic therapies, and strong momentum in gene-targeted treatment development. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71656 Huntington's
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market was valued at USD 2.15 billion in 2024 and is projected to reach USD 3.95 billion by 2034, expanding at a CAGR of 6.1%
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market was valued at US …
Market Overview The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market was valued at USD 2.15 billion in 2024 and is projected to reach USD 3.95 billion by 2034, expanding at a CAGR of 6.1% during the forecast period. CIDP is a rare autoimmune neuropathy marked by progressive weakness, sensory loss, and impaired motor function due to demyelination of peripheral nerves. Rising disease awareness, improved diagnostic techniques, and increasing availability of immunomodulatory therapies are
Hemophilia B Market is projected to reach USD 9.81 billion by 2034
Hemophilia B Market is projected to reach USD 9.81 billion by 2034
The global Hemophilia B Market was valued at USD 4.76 billion in 2024 and is projected to reach USD 9.81 billion by 2034, growing at a CAGR of 7.5% during the forecast period (2025-2034). The market is expanding rapidly due to increasing access to factor IX replacement therapies, adoption of long-acting recombinant products, significant improvements in diagnostic capabilities, and strong momentum in curative gene therapy. Download Full PDF Sample Copy of
Facioscapulohumeral Muscular Dystrophy (FSHD) Market is projected to reach USD 482 million by 2034
Facioscapulohumeral Muscular Dystrophy (FSHD) Market is projected to reach USD 4 …
The global Facioscapulohumeral Muscular Dystrophy (FSHD) Market was valued at USD 210 million in 2024 and is projected to reach USD 482 million by 2034, expanding at a CAGR of 8.6% during the forecast period (2025-2034). The market is driven by rising diagnosis rates, advancements in genetic testing, improved clinical awareness among neuromuscular specialists, and accelerating drug development targeting the underlying molecular mechanisms of FSHD. Download Full PDF Sample Copy of

All 5 Releases


More Releases for CIAS

Cognitive Impairment Associated with Schizophrenia (CIAS) Market Detailed Indust …
Introduction Schizophrenia is a chronic psychiatric disorder affecting approximately 1% of the global population, often characterized by hallucinations, delusions, and social withdrawal. However, beyond these hallmark symptoms, cognitive impairment associated with schizophrenia (CIAS) remains one of the most debilitating aspects of the disease. CIAS manifests as deficits in memory, attention, problem-solving, and executive function, severely limiting patients' ability to live independently, pursue employment, and maintain social relationships. While traditional antipsychotics effectively manage
Perimeter Protection Market Next Big Thing | Major Giants Bosch Security Systems …
Advance Market Analytics published a new research publication on "Perimeter Protection Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Perimeter Protection market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy of
Network Intrusion Detection System (NIDS) Market | American Dynamics, CIAS Elect …
The global network intrusion detection system (nids) market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the network intrusion detection system (nids) market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the
Intruder Detection Systems Market | American Dynamics, CIAS Electronica, CP Elec …
The global intruder detection systems market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the intruder detection systems market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
Cognitive Impairment Associated With Schizophrenia (CIAS) Research Report (2017)
Albany, New York, March 15, 2017: Market Research Hub has recently announced the report on “Cognitive Impairment Associated with Schizophrenia”. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated with Schizophrenia (CIAS) Pipeline Review, H1 2017, provides an overview of the Cognitive Impairment Associated with Schizophrenia (CIAS) (Central Nervous System) pipeline landscape. Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor
Global Cognitive Impairment Associated With Schizophrenia (CIAS) Clinical Trials …
The report analyzes and presents an overview of " Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H2, 2016 " worldwide. GlobalData's clinical trial report, Cognitive Impairment Associated With Schizophrenia (CIAS) Global Clinical Trials Review, H2, 2016" provides an overview of Cognitive Impairment Associated With Schizophrenia (CIAS) clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Impairment Associated With Schizophrenia (CIAS).